INDUSTRY UPDATE UK base for global IVF technologies company
Discovery Park, one of Europe’s leading science and technology parks, has announced the arrival of Genea Biomedx, the Australian in vitro fertilisation (IVF) technologies company to its site. Launched by fertility group Genea earlier this year, Genea Biomedx is developing practical, accessible and precise technology to improve IVF laboratory outcomes. The company will move into its new
building later this year and plans to recruit around 30 new staff for the facility at Discovery Park in Sandwich, which will take the total number of people employed on the site to over 1400. Discovery Park is also in discussions with three other science-focused organisations, which would bring a further 300 jobs to the site in the south-east.
www.geneabiomedx.com
Urine collection brought up to date
Vacutest urine collection is the latest innovation from Elkay Laboratory Products (UK), providing a safe, patient friendly, mess-free alternative to decanting urines in your laboratory. If you missed the launch at the recent Biomedical Science Congress, go online for more information on Vacutest. Also, for a no-fuss, no-mess solution to urine collection, contact Elkay (
sales@elkaylabs.com) or go online to see the latest products for 2013–14.
www.elkaylabs.com
Dengue virus serotypes from human cell lines
All four dengue virus NS1 serotypes have been manufactured in response to the unmet need for highly purified, concentrated proteins for use in vaccine development and serology-based diagnostic assays. To achieve this, The Native Antigen Company has employed its novel VirTuE platform, which is based entirely on human cell lines using state-of-the-art expression techniques.
Dr Holger Hannemann, lead scientist at The Native Antigen Company, said: “Our aim was to focus on NS1’s native hexameric presentation. The hexamer is believed to be the biologically active form of NS1 involved in key aspects of dengue pathogenesis. The resultant NS1 proteins are purified, are in their native folding state, and possess all post-translational modifications. This advanced approach results in a product that delivers optimal antigenicity due to its human origin.”
With more than one-third of the world’s Haemoglobin variant testing: the complete diagnostic solution
Menarini Diagnostics has been the market leader in the UK for HbA1c testing since the introduction of the HA-8110 in 1982. Over the following 30 years the company launched the HA-8120, HA-8140 and HA8160. This year saw the introduction of the HA-8180, which takes HbA1c analysis to a new level of precision. In 2012 Menarini Diagnostics launched the Hb9210 boronate affinity high-performance liquid chromatography (HPLC) analyser, which
offers speed, accuracy and precision, and no interference from haemoglobin variants. This year saw the introduction of the B-analyst, a point-of- care HbA1c analyser that provides laboratory instrument performance. In early 2014 Menarini Diagnostics will launch the Hb9210 ion exchange HPLC analyser giving HbA1c, HbA2, HbF and haemoglobin variant detection. The Menarini Diagnostics package will comprise HA-8180V for fast HbA1c and
haemoglobin variant detection, Hb9210 boronate affinity method for the fastest HbA1c with no interference from haemoglobin variants, Hb9210IEX for HbA1c, HbA2, HbF and haemoglobin variant detection, and the B- analyst HbA1c analyser giving laboratory performance in a point-of-care setting – the complete solution in HbA1c, β-thalassaemia and haemoglobin variant analysis.
www.menarinidiag.co.uk
population living in areas at risk of virus transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics. As many as 100 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes, and there are no vaccines available to prevent infection with dengue virus.
www.thenativeantigencompany.com
Point-of-care CRP analyser evaluation
Horiba UK has announced the successful outcome of an evaluation study of a point-of- care (POC) full blood count (FBC) and whole blood C-reactive protein (CRP) comparison study of its Microsemi CRP analyser. The study was undertaken by Synergy Health Laboratory Services and confirms that this easy-to-use POC analyser demonstrates excellent correlation with routine methodologies. C-reactive protein is secreted by the liver in response to various inflammatory cytokines and is often used for the diagnosis and monitoring of different acute inflammatory processes, particularly in a near-patient setting where it can rapidly evaluate possible infection and sepsis. Immediate availability of CRP results using devices such as the Microsemi CRP has been shown to reduce antibiotic use and improve the rapid detection of increased risk of major co-morbidities in patients with chronic obstructive pulmonary disease (COPD). Microsemi CRP requires just 18 µL of whole blood for the simultaneous measurement of FBC, including three-part differential, and CRP within four minutes. The study found that the instrument demonstrated excellent correlation for FBC, differential and CRP when compared to routine methods, and confirmed its suitability for use in primary and secondary care, as well as in the paediatric setting.
www.horiba.com/uk/medica
716
THE BIOMEDICAL SCIENTIST
DECEMBER 2013
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58